Nautilus Biotechnology Raises $76 Million in Series B Funding to Be the First to Quantify the Human Proteome
Amount Raised
$76 Million
Round Type
Series B
SeattleOtherBiotechnologyHealth CareLife ScienceDescription
Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for analyzing and quantifying the human proteome, today announced it has raised $76 million in an oversubscribed Series B offering that closed on Monday, May 18, 2020. Nautilus’ total funding now exceeds $100 million. The Nautilus platform will deliver single-molecule sensitivity more quickly, more completely, and less expensively than is possible with existing technologies. This deeper, richer understanding of proteins will enable a dramatic acceleration of basic science research, significantly improve the success rate of therapeutic development, and speed the adoption of personalized and predictive medicine.
Quick answer
Nautilus Biotechnology raised $76 Million in a Series B round, dated May 21, 2020. Nautilus Biotechnology is based in Seattle, Washington, United States.
- How much did Nautilus Biotechnology raise?
- Nautilus Biotechnology raised $76 Million in a Series B round on May 21, 2020.
- What does Nautilus Biotechnology do?
- Nautilus Biotechnology, Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome.
- Where is Nautilus Biotechnology based and how big is it?
- Nautilus Biotechnology is based in Seattle, Washington, United States. Fundz records about 173 employees.
- Who are the decision-makers at Nautilus Biotechnology?
- Fundz holds 5 contacts at Nautilus Biotechnology. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Life Science and Biotechnology around the same time
Companies in the same sectors as Nautilus Biotechnology that raised within 45 days of this round, from Fundz verified event records.
- Imbria Pharmaceuticals raised $67M on July 2, 2020.
- Amylyx Pharmaceuticals raised $30M on July 1, 2020.
- Kerecis raised $110K (Seed) on July 1, 2020.
- SRX Global Inc. raised $1.5M (Seed) on June 30, 2020.
- Helus Pharma raised $1.5M on June 29, 2020.
- Artiva Biotherapeutics raised $78M (Series A) on June 26, 2020.
Who to call at Nautilus Biotechnology, and when
A new round usually means Nautilus Biotechnology is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nautilus Biotechnology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nautilus Biotechnology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nautilus Biotechnology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nautilus Biotechnology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNautilus Biotechnology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.